

July 8, 2022

From Eric's Desk

Happy July 8th. The summer is fully upon us. I know everyone is keen to be productive, especially as we come to another lull (of sorts) in the pandemic, but please take some time off to relax and enjoy the weather, time outside, family, and friends. I worry that everyone must be reminded too many times to take vacation time.

I am truly thrilled to announce that Cecelia (Cece) Calhoun, MD, MPHS, MBA, is the new Director of our Sickle Cell Program. Cece is unquestionably the right person to take on this role. She had outstanding fellowship training at Washington University in St. Louis and was in the inaugural class of the Pozen-Commonwealth Fund Fellowship in Health Equity Leadership here at Yale School of Management. She is not only exceptionally bright but has tremendous emotional intelligence and in a brief year at Yale has demonstrated her remarkable leadership skills.

As discussed in a **recent article**, perhaps no other group of patients has suffered more from the impact of systemic racism in the United States than those with sickle cell anemia. As a cancer center, we are fully committed to reversing the horrific challenges that have been faced by the sickle cell community. We not only need to develop new and better therapies but must attend to the day to day medical and psychosocial needs of this group of patients and their families. Cece lives this mission daily through her clinical work and her research, and under her leadership I am convinced that our sickle cell program will thrive—providing outstanding clinical care, researching critical questions, and playing a major role in altering the trajectory of the disease. Congratulations, Cece!

As I was about to sign off, I saw an email from Anna Raso who knew I was going to be writing this blog today and thoughtfully suggested that I might invite others to write in the space. So, (of course) she provided me with an example, written early this morning, and a tribute to Cece. It is incredible and I have added it below.

Eric

As Chief of Staff to Dr. Winer (here is where he would tell me to call him Eric), I have the privilege of meeting so many talented and engaging people across our cancer enterprise. Building that network is a critical part of my role

in supporting the Director and is truly the part that I enjoy the most about my job. Over the last few years overseeing faculty recruitment operations for

Eric P. Winer, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Network


Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER CENTER**
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center

Disparities in Cancer Immunotherapy Use

Persist After FDA Approval



[Read More](#)

**Sarcoma Awareness Q&A with Hari
Deshpande, MD**



job. Over the last years overseeing faculty recruitment operations for Yale Cancer Center, interacting with our incoming recruits from the very beginning of their journey coming to Yale has helped me to establish a strong bond with some of my favorite collaborators who have since joined our team. Without a doubt, I can usually tell how each new relationship is going to play out based on those early interactions. Were they engaged? Were they nice? Did they respond to my emails in a coherent way?

In one of my very first search committee meetings, Cathy Lyons [former CNO] turned to me and said “Anna, I want to know how they treated you—how a potential recruit treats staff can tell a lot about their character and future success here.” In that moment, Cathy gave me a voice at a table I didn’t even know I was really sitting at and reinforced the importance of character and empathy in the people we want to join our team.

On a chilly day in late October 2020, I walked over to the East Pavilion to meet a recruit at Occupational Health—she had just flown in from St. Louis and needed to be COVID tested per our visitor restrictions at the time before we could start her official “recruitment visit.” I remember it being a gray day but that didn’t matter once Dr. Cecelia Calhoun (this is where she would tell me to call her Cece) walked into the waiting room—she was like sunshine with a negative test result, and we were on our way with our day! It was a day of gallivanting around campus from meetings to a dinner over takeout in a conference room with half the attendees joining via Zoom from their homes. There was something about Cece’s energy and enthusiasm that made anything seem possible—I remember thinking, “If we can bring this energy here, we can do big things.”

As of July 1st, Cece has been promoted to Director of the Sickle Cell Program and it is so exciting to be able to see that energy do big things for our patients and our team overall. Cheers to you, Cece!

Anna

Announcements

Kiran Turaga, MD, MPH, Appointed Chief of Surgical Oncology

We are pleased to announce the appointment of Kiran Turaga, MD, MPH, Division Chief of Surgical Oncology in the Department of Surgery and Assistant Medical Director for the Clinical Trials Office at Yale Cancer Center, effective October 1, 2022. Dr. Turaga joins Yale Cancer Center and Smilow Cancer Hospital from the University of Chicago where he is Vice Chief of the Section of

General Surgery and Surgical Oncology, Director of the Surgical Gastrointestinal Cancer Program,



[Read More](#)

Smilow Shares Survivorship Series: Shop Savvy for Survivors—Eat healthy on a budget



[Watch Now](#)

Blockchain Not Just for Bitcoin: It can Secure and Store Genomes, Too



[Read More](#)

Closer to Free Funds Lifesaving Clinical Trial for Smilow Patient



[Watch Now](#)

Bold Plans for Cancer Care at Yale



and Director of Regional Therapeutics.

Widely considered a thought leader in the management of oligometastatic cancer, Dr. Turaga is an expert in regional perfusion including hyperthermic intraperitoneal chemotherapy (HIPEC), a technique that delivers high doses of heated chemotherapy directly to abdominal organs to kill cancer cells that may remain after surgical removal of visible tumors.

His research focuses on development of novel diagnostics and therapeutics for oligometastatic cancer and is currently the principal investigator on several clinical trials exploring the interface of immunotherapy and liquid biopsy in the surgical management of cancer. He is also interested in studying how big data systems can be used to provide the most optimal, cost-effective patient care.



Jacquelyne Gaddy, MD, MSc, joins Center for Gastrointestinal Cancers

Dr. Jacquelyne Gaddy has been appointed as an Assistant Professor in the Department of Medicine (Medical Oncology) and will care for patients as part of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center beginning on August 1. Dr. Gaddy received her medical degree from Loyola University and her MSc in Cancer Sciences at the University at Buffalo. She completed her residency at the University at Buffalo and while a fellow in hematology/oncology at the University of North Carolina at Chapel Hill, undertook a post-doctoral fellowship in the Department of Health Behavior.



Dr. Gaddy has dedicated her entire postgraduate career to focusing on improving diversity, equity, and inclusion. She is committed to improving cancer care delivery for Black patients while also addressing the needs of Black, Indigenous, People of color (BIPOC) cancer care providers through an educational and investigational approach. Her primary research focus is on racial/ethnic disparities and improving health outcomes in the treatment of solid tumors. She is a 2012 recipient of the Medical Student Rotation for Underrepresented Populations and a 2019 recipient of the Resident Travel Award for Underrepresented Populations from Conquer Cancer, the ASCO Foundation.

Cece Calhoun, MD, MPHS, MBA, Appointed Director of the Sickle



[Read More](#)

Defining the Landscape of Prostate Cancer Treatment



[Read More](#)

Follow us!

facebook



YouTube

Instagram

YALE CANCER ANSWERS

Cell Program at Smilow Cancer Hospital

Cecelia (Cece) Calhoun, MD, MPHS, MBA, Assistant Professor of Medicine (Hematology) and of Pediatrics (Hematology/Oncology), has been appointed Director of the Sickle Cell Program for both adults and pediatrics at Smilow Cancer Hospital. Dr. Calhoun cares for adolescents and young adults with Sickle Cell Disease (SCD) as part of the Smilow Cancer Hospital Pediatric and Adult Hematology Programs.




Dr. Calhoun uses mixed methods to find solutions to the educational and healthcare obstacles critical to the longevity of adolescents with sickle cell disease. She has dedicated her career to the design and implementation of evidence-based interventions that promote successful transition from youth to adult care for the sickle cell population. As an NIH-funded investigator, she collaborates with her hematology colleagues across the nation to use Implementation Science methods to improve outcomes for patients with sickle cell disease throughout their lifespans.

Born in Detroit, Michigan, Dr. Calhoun graduated from the University of Michigan with a Bachelor of Arts degree in Afro-American Studies and Medical Doctorate from Wayne State University. She continued her training at Michigan State University as a pediatric resident, then fellowship at Washington University School of Medicine where she also completed a Master of Population Health Sciences. She received her MBA as one of three, inaugural Pozen-Commonwealth Fund Fellows in Minority Health Equity Leadership at Yale University.

35 Years of Mobile Mammography!



We are pleased to share that our Spring | Summer 2022 issue of Centerpoint Magazine is now available, featuring the latest research and clinical advances from Yale Cancer Center and Smilow Cancer Hospital!



[Read More](#)

Yale Cancer Center's Genetics, Genomics, and Epigenetics Research Program welcomes He (Peter) Wang, MD, PhD, Associate Professor of Pathology. Dr. Wang is a board-certified anatomic pathologist with subspecialty training in cardiovascular and lung pathology and Director of the Cardiovascular Pathology section for Yale Pathology. Dr. Wang's lab is focused on studies of biological effects of E-cigarette, including mtDNA damage, systematic inflammation biomarkers, atherosclerosis, combined effects of E-cigarette and Vitamin E on lung damage, and tumor metastasis. Welcome, Dr. Wang!



[Read More](#)

Tune in to Yale Cancer Answers, Dr. Beth Jones and Monique Stefanou will discuss ways to address cancer disparities at the community level. Listen in on Connecticut



Join us in celebration of our Mobile Mammography Unit's 35th anniversary on Wednesday, July 27 from 11:30am-1:00pm at One Long Wharf. Come visit the unit and meet the staff as we celebrate caring for the community since 1987. Ice cream and light refreshments will be served.

Notables

The **Center for Community Engagement and Health Equity**, directed by Marcella Nunez-Smith, MD, MHS, has selected three Yale Cancer Center investigators to be funded to take part in the year-long **"Foundations of Community-Engaged Research"** course offered through the **National Clinician Scholars Program**. Congratulations to **Jacquelyne Gaddy, MD, MSc**, Assistant Professor of Medicine (Medical Oncology), **Anup Sharma, PhD**, Research Scientist in the Department of Surgery, and **Sandra Zaeh, MD MS**, Instructor of Medicine (Pulmonary and Critical Care Medicine).

Haifan Lin, PhD, Eugene Higgins Professor of Cell Biology, and Professor of Genetics, of Obstetrics, Gynecology & Reproductive Sciences, and of Dermatology; Director, Yale Stem Cell Center; and a member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Research Program, has been named **President of the International Society for Stem Cell Research**. The society includes more than 4,400 members from more than 70 countries and is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic.

Dhanpat Jain, MD, Professor of Pathology and of Medicine (Digestive Diseases) and a member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Research Program, has been named to the **Cancer Committee of the College of American Pathologists (CAP)**, the leading organization of board-certified pathologists that fosters and advocates excellence in the practice of pathology and laboratory medicine worldwide.

Diversity, Equity, and Inclusion

First Vice Chair for Diversity, Equity & Inclusion appointed by Yale Surgery

Paris Butler, MD, MPH, FACS, has been named Vice



Public Radio or download our podcast from iTunes.



[Read More](#)

Congratulations to Suzanne Evans, MD, MPH, on her selection by the American Society for Radiation Oncology (ASTRO) to receive the ASTRO Fellow (FASTRO) designation. The ASTRO Fellows program recognizes individuals who have made substantial contributions to the Society and to the field of radiation oncology through research, education, patient care, and service to the field. Dr. Evans will be formally recognized at an awards ceremony this fall during ASTRO's 64th Annual Meeting.



[Read More](#)

"To inspire an engaged team to deliver innovative, patient-centered care with world class outcomes – one surgery, one family, one patient at a time." - Caitlin Cahill, MSN, RN

Today, our #SmilowStars are the incredible team from our North Pavilion Operating Rooms who support our patients and surgeons in the 12 operating rooms at Smilow Cancer Hospital. Together, there are approximately 45 staff members, including circulating nurses, surgical technologists, specialty coordinators, and an assistant manager. The team is led by Caitlin Cahill, MSN, RN, Patient Services Manager (PSM).

"The North Pavilion Operating Room team is a truly remarkable and dedicated group of professionals. They provide support for the entire spectrum of surgeons that care for cancer patients. They impress me every day with their great attitudes, warmth, caring, and commitment to growth and innovation," said Kevin Billingsley, MD, MBA, Chief Medical

Chair for Diversity, Equity & Inclusion (DEI) and is the first Vice Chair of DEI in the Department of Surgery's 209-year history. He is also an Associate Professor in the Division of Plastic Surgery at Yale School of Medicine, and cares for patients as part of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center in New Haven and at the Smilow Care Center in Guilford.



As the inaugural Vice Chair for DEI, Dr. Butler will be charged with elevating a strategic vision for expansion of DEI activities, working in coordination with Vice Chairs, Division Chiefs, and Program Directors to actively promote a comprehensive approach to recruitment, retention, and support of highly qualified, diverse, and talented faculty, staff, residents, and fellows. He received his MPH from University of California, Berkeley in health policy and management with special certificate in minority health. Dr. Butler is nationally recognized for his dedication to reducing healthcare disparities along ethnic lines – something he has approached with research, policy, and teaching in mind.

"Diversity is at the center of our responsibility to transform healthcare and lead academic medicine into the future. I am excited to partner with my colleagues at Yale, and especially in the Department of Surgery, to make the place where we work, educate, and care for our patients, a more inclusive and respectful place for everyone," said Dr. Butler.

Dr. Butler received his medical degree at the University of Virginia School of Medicine, completed a general surgery residency at the University of Virginia, and completed his plastic surgery training at the University of Pennsylvania. He is a Fellow of the American College of Surgeons (FACS) and his clinical interests within cancer care are breast reconstruction, scar/wound management, breast implant removal, and aesthetic surgery. His research interests include keloid pathophysiology and treatment, surgical health care disparities, health care policy, and provision of care to the underserved.

Kevin Billingsley, MD, MBA, FACS, Professor of Surgery (Oncology) and Chief Medical Officer for Smilow Cancer Hospital and Yale Cancer Center, commented on Dr. Butler's historic appointment, "We are enormously fortunate to have Dr. Butler joining the Department of Surgery and Yale Cancer Center community. He brings an extraordinary wealth of experience, perspective, and leadership. His contributions will be invaluable as we work to continuously develop our organization as a national leader in diversity, health equity, and a culture of inclusion."

Responding to the Decision in *Dobbs v. Jackson Women's Health Organization*

Many within the oncology community have viewed the recent Supreme Court decision overturning *Roe v. Wade* with alarm, and highlighted its violations of core medical principles of autonomy, beneficence, and justice. Eric Winer,

Kevin Billingsley, MD, MBA, Chief Medical Officer at Smilow Cancer Hospital and Professor of Surgery (Surgical Oncology).



Read More

Congratulations to Cynthia James, Clinical Operations Manager at Smilow Cancer Hospital! Cynthia was awarded an Honorary Doctor of Humane Letters by Charter Oak State College during their commencement ceremony on June 5.

This prestigious honor is awarded annually by the Connecticut Board of Regents for Higher Education and Charter Oak State College "to an individual or individuals who have made exceptional contributions to the College and to local, national and/or international communities and who have influenced advances within their own professional fields."

It was said of Cynthia during the bestowment, "Beyond Charter Oak State College, Cynthia's compassion, grit, and commitment to social responsibility reaches beyond her professional accomplishments. As a Clinical Operations Manager at Smilow Cancer Hospital, Cynthia works with patients who face serious medical challenges. Her care and acts of compassion are authentic and personal, being a cancer survivor herself. Additionally, she serves on advocacy committees and chapters outside of her current role as Clinical Department Liaison at Yale Cancer Center including serving as a Patient Representative for the Patient and Family Advocacy Committee who, in partnership with the Yale New Haven Health

System, advocates for access for minority and under-represented patients to help achieve high quality, safe, patient-centered care...Cynthia's activism in support of the business of healthcare and patient care, with a focus on providing support for accessibility to minority groups is one founded on her love of and empathy for the field. Her exceptional contribution to the College, to her local communities, and service to advance her professional field is precisely the sort of excellence that Charter Oak aspires to for all

...the medical principles of autonomy, beneficence, and justice. Dr. Winer, MD, wrote about the ways in which this decision will directly interfere with the medical care of patients with cancer, and noted that 1 in 1,000 pregnancies is touched by cancer. His comments, as well as those of other leaders in cancer medicine were covered in a recent issue of **The Cancer Letter**. Several YCC members sit on the **Committee on the Status of Women in Medicine (SWIM)**. SWIM addressed the ways in which loss of reproductive freedom threatens women's integration in the medical and biomedical science workforce as the ability to undertake long and arduous training, move for advanced training or highly subspecialized work opportunities, and avoid extended career gaps is constrained. Yale Cancer Center members Valerie Horsley, PhD, and Paula Kavathas, PhD, also spoke at rally for reproductive rights at YSM on June 24th.

To read more, here are links to recent statements and coverage:

Dr. Eric Winer's Statement to the YCC/Smilow Community

The Cancer Letter

SWIM Statement

AACR Statement

DEI Climate Survey

Yale Cancer Center and Smilow Cancer Hospital are committed to building a diverse and welcoming community. To help us achieve our goals, we ask you to participate in our climate survey to share your experiences and your view of diversity, equity, and inclusion. The data will be analyzed by an independent consultant (The Barthwell Group), and your answers will remain completely anonymous. We urge you to be candid – only by truly understanding barriers faced by some in our community will we be able to dismantle those barriers. The results will be most meaningful with high participation.

The survey for Yale Cancer Center members, trainees, and employees launched on June 15th by email from Dr. Winer's office. You may access the survey through this [link](#). The survey link will close on July 22. Please take these few minutes to make sure we hear your voice!

Employee Profile: Audrey Baluha, RN

Audrey Baluha, RN, has been working with the Classical Hematology Program at the Smilow Cancer Hospital Care Center in North Haven for almost

five years. In her current role as practice nurse, Audrey is responsible for triaging a large volume of patients with complex medical needs and assisting in high-level care coordination and planning alongside a team of physicians and advanced practice providers.

Classical hematology is also




...excellence that Charter Oak aspires to for all its students.”

Congratulations, Cynthia! We are so proud!



[Read More](#)

Did you know our YouTube channel has a dedicated playlist for all of our Smilow Shares Survivorship content? Topics include nutrition, fear of recurrence, exercise, sexuality and intimacy, and more, and can be a great resource for patients and survivors of cancer or friends and family members. Each video can be viewed on a laptop, smart phone, or tablet.



[Read More](#)

Paul Egan of Clinton is known as “The Bike Guy,” fixing up and giving away bicycles to members of the community throughout the year. After a cancer diagnosis in the summer of 2021 and an initial feeling of helplessness, Paul with wife Liz, decided to participate in the Closer to Free Ride , starting “Team Bike Guy Boosters” – and members of the community joined the couple. This year, the Egans intend to ride again with a goal to raise \$50,000 for Yale Cancer Center and

referred to as benign hematology or non-malignant hematology. Patients present with medical conditions most often related to bleeding or thrombosis. Due to the complex nature of the disorders, patients require a significant amount of education, which is

where Audrey has found a natural fit and discovered a passion for both patient and staff education. In May, Audrey earned a Master of Science in Nursing (MSN) from Sacred Heart University, with a specialization in nursing education, and she hopes to teach at the collegiate level in the future.

Audrey started her nursing career at Yale New Haven Hospital in 2014, working as a staff nurse in general surgery and later the surgical ICU, but transitioned to outpatient hematology in 2017. Audrey values the close-knit relationships within the practice, which has fostered a team atmosphere and a multidisciplinary approach to patient care.

Natalia Neparidze, MD, says, "It is truly a pleasure working with Audrey. She is highly professional, dedicated, extremely hard-working, diligent, and reliable. She puts 100% effort and pours her energy, heart, and soul into working with patients in Classical Hematology. In addition to her outstanding professionalism, Audrey is a wonderful human being, kind, compassionate, devoted to providing care to patients as if they were her own family."

Echoing Dr. Neparidze's comments, Sabrina Browning, MD, says, "Audrey consistently provides the highest quality, patient-centered care, always going above and beyond for her patients and colleagues. She is an integral member of our team due to her unwavering dedication to our patients and her hard work. She is also always able to spark laughs among our team even on the busiest of days."

Lastly, Audrey's coworker, Anne Dumont, RN, shares, "Audrey has been a terrific colleague since the day I started orienting her in Classical Hematology. Her attention to detail, 100% accountability, and relentless commitment to providing the best patient care possible are a daily inspiration. She is a gifted educator, and her patients and peers are lucky to have her!"



Smilow Cancer Hospital, giving back to the hospital where Paul stayed for four months and where he witnessed many moments of compassion and respect towards fellow patients.

Compassionate care—and personal experience—inspire Paul Egan to give back.



[Read More](#)

Tune in to Yale Cancer Answers to hear Dr. Stavroula Hatzios discuss her research into Advancing our Understanding of Gastrointestinal Diseases. Listen on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

Recent Publications

Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF.

Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period

Leukemia, Online ahead of print.

[Read More](#)

Kahn, AM, Blenman, K, Sonis, ST, Lustberg, MB.

Strategies to mitigate the toxicity of cancer therapeutics.

Advances in cancer research, 155, 215–244.

[Read More](#)

Fernandez AL, Gavriolatou N, McCann L, Shafi S, Moutafi MK, Martinez

Yale New Haven Children's Hospital (YNHCH), the top-ranked children's

hospital in Connecticut, received a national ranking for pediatric oncology care in the Best Children's Hospitals rankings, published this month by U.S. News & World Report.

The rankings placed YNHCH among the best children's hospitals in the nation for eight out of ten pediatric subspecialties including Diabetes and Endocrinology (#18); Gastroenterology and GI Surgery (#24); Neurology and Neurosurgery (#30); Urology (#30); Pulmonology and Lung Surgery (#31);

Fernandez AI, Gavrielatou N, McCarin L, Shair S, Moutari MK, Martinez-Morilla S, Vathiotis IA, Aung TN, Yaghoobi V, Bai Y, Chan YG, Weidler J, Herbst R, Bates M, Rimm DL.

PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer

Journal of Thoracic Cancer, Online ahead of print.

[Read More](#)

Ahmed M, Muradashvili T, Soliman S, Ghaly M.

Metastatic insidious super giant basal cell carcinoma

BMJ Case Reports, 15(6):e249873

[Read More](#)

Kim IE Jr, Kim DD, Kim S, Ma S, Jang TL, Singer EA, Ghodoussipour S, Kim IY.

Changes in prostate cancer survival among insured patients in relation to USPSTF screening recommendations

BMC Urology, 22(1):91.

[Read More](#)

Oria VO, Zhang H, Zito CR, Rane CK, Ma XY, Provance OK, Tran TT, Adeniran A, Kluger Y, Sznol M, Bosenberg MW, Kluger HM, Jilaveanu LB.

Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma

Cellular and Molecular Life Sciences, 79(7):377.

[Read More](#)

Burkhardt DB, San Juan BP, Lock JG, Krishnaswamy S, Chaffer CL.

Mapping Phenotypic Plasticity upon the Cancer Cell State Landscape Using Manifold Learning

Cancer Discovery, Online ahead of print.

[Read More](#)

Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM.

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low or intermediate-1 risk myelodysplastic syndrome

Haematologica, Online ahead of print.

[Read More](#)

Knowlton CA, Jimenez RB, Moran MS.

Risk Assessment in the Molecular Era

Seminars in Radiation Oncology, 32(3):189-197.

[Read More](#)


Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD.

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Gynecologic Oncology, 166(1):117-125

Nephrology (#41); Neonatology (#44); and Cancer (#45).

Smilow Cancer Hospital and Yale New Haven Children's Hospital's care team works with our patients and their families to design a treatment plan based on the individual's needs. In addition to a pediatric oncologist, our multidisciplinary team includes advanced practice providers, registered nurses, social workers, a psychologist, psychiatrist, neuropsychologist, nutritionist and child life specialists, all who have expertise in the medical, social, emotional and educational needs of our youngest patients.



[Read More](#)



.@JAMANetworkOpen

shared a review of Dr. Daniel Boffa's

recent research on the disparities of #clinicaltrial participation & access to #immunotherapy for patients with #melanoma, #kidneycancer, and #lungcancer.



Our Spring | Summer 2022 issue of #Centerpoint Magazine is now

available, featuring the latest research and clinical advances from @YaleCancer and @SmilowCancer!



A paper from Dr. Muhammed Shareef @YaleRadiology

provides a comprehensive overview for radiologists to better understand and interpret the complications of #lymphoma in the abdomen and pelvis.



A recent study from Drs. Meena Moran & Christin Knowlton reviews

the status of #geneticstesting for personalized risk assessment for #DCIS and the likelihood

Gynecologic Oncology, 166(1):111-120.

[Read More](#)

Khang M, Bindra RS, Mark Saltzman W.

Intrathecal delivery and its applications in leptomeningeal disease

Advanced Drug Delivery Reviews, 186:114338.

[Read More](#)

Mokhtech M, Gao SJ, Kassick M, Menderes G, Damast S.

Declining use of inguinofemoral lymphadenectomy in the treatment of clinically negative, pathologic node positive vulvar cancer

Gynecologic Oncology, 166(1):61-68.

[Read More](#)

Jairam V, Park HS, Yu JB, Bindra RS, Contessa JN, Jethwa KR.

Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy

Advances in Radiation Oncology, 7(4):100949.

[Read More](#)

Chapiro J.

Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma

Journal of Hepatology, 77(1):6-8.

[Read More](#)

Funding and Award Opportunities

The Mark Foundation for Cancer Research: 2023 Mark Foundation Endeavor Award

These awards support teams of scientists with diverse areas of expertise to address urgent problems in cancer research. The Endeavor Award program enables teams of three or more investigators to tackle challenges in cancer research that are too large for any single lab to address alone. Endeavor Awards are \$3 million grants disbursed over a three-year term.

Internal Deadline: July 13, 2022

[Read More](#)

Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54)

The purpose of this FOA is to invite applications for TCORS to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the Research Objectives related to the regulatory authority of the FDA Center for Tobacco Products.

Application Deadline: July 14, 2022

[Read More](#)

Damon Runyon Cancer Research Foundation: Damon Runyon-Dale F. Frey Award for Breakthrough Scientists 2022

The Damon Runyon Fellowship identifies the nation's top postdoctoral fellows and provides funding that enables them to complete their training under the mentorship of a leading senior scientist and encourages them to follow their

risk assessment for #DCIS and the likelihood that most low-risk DCIS patients are overtreated.



Tonight at 7:30pm on Yale Cancer Answers, Dr. Beth Jones and

Monique Stefanou will be discussing ways to address #cancerdisparities at the community level. Listen live on @wnpr or download our podcast from iTunes.



"2022 will be a growth year for #sarcomas at @YaleCancer. I hope to bring new and exciting #clinicaltrials for our patients and improve the standard care for all of our patients." Hari Deshpande, MD.



Congratulations SueEvansMDMPH !Selected by @ASTRO_org to receive the ASTRO

Fellow #FASTRO designation recognizing substantial contributions to #radiationoncology through research, education, patient care & service @YaleRadOnc



Paul Egan, "The Bike Guy" and recent patient at Smilow Cancer

Hospital, will ride in his 2nd @ctfride with a goal to raise \$50k for @YaleCancer @SmilowCancer. He was recently featured on @NBCConnecticut



.@ElizabethPrsic and @faizayasin_md write how persons living with #HIV and #cancer need earlier #PalliativeCare engagement to integrate their HIV care with #cancercare + avoid medication toxicity.



Tune in tonight at 7:30pm to Yale Cancer Answers to hear Dr.

Stavroula Hatzios discuss her research into Advancing our Understanding of Gastrointestinal Diseases. Listen live on @wnpr or download our podcast from iTunes.



Congratulations to Marie Robert, MD, @YaleMedicine

Distinguished Clinical Career Award recipient in recognition of contributions & dedication to advance Yale Medicine, the medical profession, and the community.



A recent study from elizabethprsic

own bold ideas. To catapult their research careers—and their impact on cancer—the Foundation will make an additional investment in these exceptional individuals by selecting them as recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists.

Internal Deadline: July 15, 2022

[Read More](#)

Innovations for Veterans QuickFire Challenge: Lung Cancer & Physical Trauma

Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the unique healthcare needs of the military community including lung cancer and physical trauma.

Application Deadline: July 15, 2022

[Read More](#)

Gateway/American Lung Association Grant Application Request

Gateway is partnering with ALA to fund innovative lung cancer clinical trials. They are looking for applications focused on one of the following topics. (1) Early detection diagnostics and (2) Metastatic disease.

Letter of Intent Due: July 26, 2022

[Read More](#)

Yale SPORE in Skin Cancer DRP and CEP Awards

Beginning September 1, 2022, these awards fund projects in amounts up to \$50,000 for one year with the possibility of competing renewal for a second year of funding. DRP and CEP projects must have promising translational research potential with application to human skin cancer. It is expected that they can evolve into projects with a clear translational component that are suitable for funding either within the Yale SPORE in Skin Cancer or as R01 or equivalent grants.

Application Deadline: July 27, 2022

[Read More](#)

Yale Head and Neck SPORE (YHN-SPORE) Developmental Research Program (DRP)

The Yale Head and Neck SPORE's DRP provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.

Full application Due: August 1, 2022

[Apply Now](#)

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement Program (CEP)

The CEP of the Yale Head and Neck SPORE has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or established investigators who have not previously conducted head and neck cancer focused research.

Full Application Due: August 1, 2022

[Apply Now](#)

DoD Breast Cancer Research Program Transformative Breast Cancer Consortium Award

This award is designed to support collaborations and ideas that will transform

 @TCarafeno @JennyXiangMD and Hari Deshpande, MD, showed how timely, post-discharge #medonc appts can significantly reduce 30-day readmission and ED visits.



Today we congratulate @maryam_justberg, director of the Breast Center at @smilowcancer and Chief of Breast Medical Oncology at @yalecancer, as she is appointed President of @cancercaremascc.



.@DrRoyHerbstYale and Dr. Sarah Goldberg shared updated data on adding nivolumab to neoadjuvant chemotherapy for early stage #lungcancer = "a gamechanger"

Calendar

Yale Cancer Answers

July 10; 7:30 PM

NPR

Agent Orange and Cancer

Rory Shallis, MD

[Learn More](#)

Yale Cancer Center Seminar

July 12; 1:00 PM

Understanding and Improving the Quality of Cancer Care

Dawn Hershman, MD, MS, FASCO

[Learn More](#)

Center for GI Cancers Journal Club

July 14; 4:15 PM

PD-1 Blockade in Mismatch Repair-deficient, Locally Advanced Rectal Cancer

Jeremy Jacox, MD, PhD

[Learn More](#)

The Fifth Annual YCC Trainee Colloquium

July 15; 8:30 AM

[Learn More](#)

Digestive Diseases Pathophysiology Seminar Series

July 15; 1:00 PM

Acute Pancreatitis

Thiruvengadam Muniraj, MD, FRCP

[Learn More](#)

Yale Cancer Answers

the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer.

Pre-application Due: August 3, 2022

Read More

DoD Breast Cancer Research Program Awards

These awards provide funding to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members, Veterans, and the general public.

- **Breakthrough Award Levels 1 and 2**- LOI Due: September 22, 2022
- **Breakthrough Award Level 3**- Pre-application Due: August 3, 2022
- **Breakthrough Award Level 4**- Pre-application Due: August 3, 2022
- **Era of Hope Scholar Award**- LOI Due: September 22, 2022
- **Innovator Award**- LOI Due: August 3, 2022

Apply Now

DoD Ovarian Cancer Research Program Clinical Trial Award

This award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.

Application Deadline: August 5, 2022

Read More

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44)

This FOA solicits SBIR applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency.

Application Deadline: August 6, 2022

Read More

Gabrielle's Angel Foundation

The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment. Of interest are innovative clinical and basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies. Focus is on projects for cancer prevention, detection and treatment that are most likely to be translated into clinical trials within a 3-5 year period.

Internal Submission Deadline: August 8, 2022

Read More

AACR-Lung Cancer Initiative at Johnson & Johnson - Stimulating Therapeutic Advances through Research Training (START)

These grants, which will provide support to postdoctoral or clinical research fellows from underrepresented groups combine research experiences in both academic and industry settings, following a research timeline that will be of greatest benefit to the proposed work.

Application Deadline: August 18, 2022

Read More

Small Business Transition Grant For Early Career Scientists (R42)

Through this FOA, the NCI, National Institute of Biomedical Imaging and Bioengineering (NIBIB), and National Institute on Drug Abuse (NIDA) intend

July 17; 7:30 PM

NPR

Cost of Cancer Care in the US

Ryan Chow and Cary Gross, MD

Learn More

Breast Friends Fund/Jennifer O'Neill Memorial Golf Tournament

July 19; 11:30 AM

Lyman Orchards Golf Course

Learn More

Yale Systems Biology Institute Summer Seminar

July 20; 1PM

Yale West Campus Conference Room

A Proteomics of Unperturbed Protein

Degradation in Escherichia coli

Martin Wühr, PhD

Learn More

Center for GI Cancers/Yale Pancreatic Cancer Collaborative Seminar

July 21; 4:15 PM

Evolution to MRI Adaptive Ablative Radiation for Unresectable Pancreatic Cancer

Christopher Crane, MD

Learn More

Share your news!

Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

Bioengineering (NIIDB), and National Institute on Drug Abuse (NIDA) intend to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses.

Application Deadline: August 22, 2022

Read More

DoD Rare Cancers Research Program Awards

There are a significant number of incidences of rare cancers in the U.S. military population. Over 60 forms of cancer disproportionately impact those who have served in the military, and 67% of them are rare cancers. These awards support research on the prevention, detection, diagnosis, and treatment of Service Members, Veterans, their families, and the American public.

- **Concept Award-** Application Deadline: August 29, 2022
- **Idea Development Award-** Application Deadline: September 30, 2022
- **Resource and Community Development Award-** Application Deadline: September 30, 2022

Read More

Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 and U34)

Through this FOA, the NCI intends to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors.

Application Deadline: September 7, 2022

Read More

DoD Melanoma Research Program Awards

These awards invest in research focusing on the prevention, detection, diagnosis, and treatment of melanoma for the benefit of Service members, Veterans, their families, and the American public.

- **Focused Program Award – Rare Melanomas – Letter of Intent**
Due: September 14, 2022
- **Melanoma Academy Scholar Award – Letter of Intent**
Due: September 14, 2022
- **Mid-Career Accelerator Award – Letter of Intent** **Due:** September 14, 2022
- **Team Science Award – Letter of Intent** **Due:** September 14, 2022

Read More

DoD Kidney Cancer Research Program (KCRP)

These awards support research of exceptional scientific merit in the area of kidney cancer.

- **Academy of Kidney Cancer Investigators Early-Career Scholar Award-** LOI Due: September 29, 2022
- **Nurse-Initiated Research Award-** LOI Due: September 29, 2022
- **Clinical Trial Award-** LOI Due: September 29, 2022

Read More

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

[Unsubscribe renee.gaudette@yale.edu](mailto:renee.gaudette@yale.edu)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by renee.gaudette@yale.edu powered by



Try email marketing for free today!